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While the introduction of combination highly active antiretroviral therapy (HAART) regimens represents an
important advance in the management of human immunodeficiency virus (HIV)-infected patients, tolerability can
be an issue and the use of several different agents may produce problems. The switch of combination HAART to
ritonavir-boosted protease inhibitor (PI) monotherapy may offer the opportunity to maintain antiviral efficacy while
reducing treatment complexity and the risks of toxicity. Current European AIDS Clinical Society (EACS) guidelines
recognise ritonavir-boosted PI monotherapy with twice-daily lopinavir/ritonavir or once-daily darunavir/ritonavir as a
possible option in patients who have intolerance to nucleoside reverse transcriptase inhibitors, or for treatment
simplification. Clinical trials data for PI boosted monotherapy are encouraging, showing substantial efficacy in the
majority of patients; however, further data are required before this approach can be recommended as a routine
treatment. Available data indicate that the most suitable candidates for the use of boosted PI monotherapy are
long-term virologically suppressed patients who have demonstrated good adherence to antiretroviral therapy, who
do not have chronic hepatitis B, have no history of treatment failure on PIs and are able to tolerate low-dose
ritonavir.Introduction
While the introduction of highly active antiretroviral the-
rapy (HAART), typically involving three drugs in combin-
ation, has been an important advance in the treatment of
people infected with human immunodeficiency type-1
virus (HIV-1), many patients do not remain on their
original treatment regimen one year after starting HAART
(EuroSIDA study; Figure 1) [1]. Common reasons for
discontinuing HAART in chronically treated patients
include patient/physician choice, treatment failure and
tolerability issues such as renal and cardiovascular toxicity
with nucleoside reverse transcriptase inhibitors (NRTIs),
and, with the non-NRTIs (NNRTIs), dyslipidaemia with
efavirenz and rash with nevirapine. Important develop-
ments for the future of HAART are to improve its potency
and activity against multi-drug resistance viruses, to* Correspondence: jrarribas.hulp@salud.madrid.org
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reproduction in any medium, provided the orimprove dosing schedules and their convenience, and to
improve the tolerability of treatment.
It is relatively common for treatment regimens to be
switched in fully suppressed HIV-1-infected patients.
These regimen switches can be either proactive (to avoid
potential problems) or reactive (in response to poor
tolerability or other issues). For example, in pregnant
women the regimen may be switched to avoid risk of
teratogenicity and to optimise pharmacokinetics, while
in other patients regimens may be switched to improve
adherence or convenience, to preserve future treatment
options, to avoid drug interactions or to reduce costs.
Maintenance of virological control is paramount when
switching therapies, and treatment switches in virologi-
cally suppressed patients was considered by the panel
members to be one of the most common therapeutic
interventions in HIV therapy in late 2011.
While intermittent therapy, sequential or prolonged treat-
ment interruptions are no longer recommended as switch
strategies by HIV treatment guidelines, [2] there remains aLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 a) Proportion of patients remaining on original
treatment regimen 1 year after initiating HAART; b) Reasons for
discontinuing HAART between 2002–2004 [1].
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deal with toxicity, to simplify treatment regimens and to try
to meet patients’ wishes for their treatment. These include
reducing pill burden, ritonavir-sparing and so-called ‘nuc’
(NRTI)-sparing regimens. Among the various switching
options available, the strategy of switching from a triple-
drug regimen to ritonavir-boosted protease inhibitor (PI/r)
monotherapy is currently a topic of some interest as it
offers a number of potential benefits, including a reduction
of NRTI-related toxicity (lipoatrophy, renal disease, bone
mineral density [BMD] loss) and reduced cost versus dual
or triple therapy while retaining other classes as future
treatment options. This review provides an overview of theuse of boosted PI monotherapy in Europe and the potential
benefits and drawbacks of such therapy.EACS 2011 guidelines on treatment switch
strategies
The current European AIDS Clinical Society (EACS)
guidelines for the management of HIV-infected patients
list three principal indications for the use of switch stra-
tegies in virologically suppressed patients (plasma viral
load < 50 HIV-1 RNA copies/mL) [2]:
 switch for toxicity – including documented toxicity,
the management of potential drug interactions, side
effects, and planned pregnancy
 switch for the prevention of long-term toxicity –
including pre-emptive switching; ageing and/or
co-morbidity with a possible negative impact of
drug(s) in the current regimen (e.g. on
cardiovascular risk and metabolic parameters)
 switch for simplification – including the wish to
simplify the regimen or because the treatment
regimen is no longer recommended.
The EACS 2011 guidelines state that PI/r monotherapy
with lopinavir twice daily or darunavir once daily might
represent an option in those patients intolerant to NRTIs,
or for treatment simplification [2]. The guidelines note that
this strategy only applies to patients without a history of
failure on prior PI-based therapy and who have had viral
load < 50 HIV-1 RNA copies/mL in at least the past
6 months. In considering a switch to boosted PI monother-
apy, attention must also be given to the duration of viro-
logical suppression prior to the considered switch, to any
pharmacokinetic/dynamic considerations, to the expected
level of adherence and to the individual patient’s needs.
Boosted PI monotherapy should not be prescribed to
patients co-infected with chronic hepatitis B.
In the USA, PI/r monotherapy is not recommended by
the Department of Health and Human Services (DHHS)
2011 guidelines outside of the clinical trial setting, [3]
and PI/r monotherapy is only recommended by the
International AIDS Society-USA (IAS-USA) 2010 guide-
lines in exceptional circumstances when other drugs
cannot be considered for reasons of toxicity/tolerability.
Other treatment guidelines offer differing recommenda-
tions with respect to boosted PI monotherapy. At
present only the EACS, [2] Italian [4] and Spanish
Gesida guidelines [5] recognise PI/r monotherapy as a
switch option in the everyday clinical setting. There is
currently a lack of consensus in the treatment guidelines
with respect to monotherapy. However, this situation
may change as the results of ongoing clinical studies of
PI/r monotherapy become available.
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At present, there is some variation in clinical practice with
regard to the use of boosted PI monotherapy between
European countries and regions (e.g. Italy where mono-
therapy tends to be only used at the larger treatment
centres). It is thought there are several reasons for this
variation. Some clinicians consider the number of patients
included in monotherapy studies to be too few for draw-
ing valid conclusions. It has been suggested that some
clinicians could be detracted from initiating boosted PI
monotherapy by potential legal implications. Finally,
geographic variation may also arise from physicians being
influenced by US guidelines and the presence of pre-
existing PI resistance.
Reasons for variability in the use of boosted PI
monotherapy in Europe
Switching from triple-drug HAART regimens to boosted PI
monotherapy offers benefits in terms of reduced com-
plexity, the potential for a reduction in some toxicities
(though longer-term data are required to more fully assess
the tolerability profile of PI/r monotherapy versus
HAART), and in terms of cost savings. However, as with
any new treatment approach, there are a number of poten-
tial issues and concerns about boosted PI monotherapy and
such concerns may at least in part account for the observed
differences in the adoption of this approach across different
European countries. There is evidence that boosted PI
monotherapy for maintenance of viral suppression is less
effective than triple-drug HAART [6]. However, the
observed difference in efficacy between HAART and PI/r
monotherapy is small and differences may be PI dependent.
Furthermore, although there is an increased risk of low-
level viraemia with monotherapy in a subgroup of patients,
this has been shown to be reversible after NRTI reintroduc-
tion. Clinical trials with darunavir/r [7-9] and lopinavir/r
[10] monotherapy have not shown an increased risk of
resistance development.
Another potential drawback of PI/r monotherapy is that
such regimens are ‘less forgiving’ of poor adherence than
triple-drug regimens, so that a high level of adherence is
required for patients switching to PI/r monotherapy. In this
regard, clinical trials have shown an association between
suboptimal adherence and virological failure in patients
treated with lopinavir/r [11,12] or darunavir/r monotherapy
[13]. It has been hypothesised that suboptimal adherence
may have a greater effect on virological suppression in
patients receiving boosted PI monotherapy than it does in
those on combination therapy including nucleosides due to
the short terminal half-lives of lopinavir and darunavir
compared with the long intracellular half-lives of nucleo-
sides [10,14]. It is in any case clear that, in addition to their
having had a sufficient period of virological suppression
on HAART (at least 6 months), candidates for PI/rmonotherapy should demonstrate a history of good adhe-
rence to prescribed treatments. In acknowledging the
importance of good treatment adherence for the success
of boosted PI monotherapy it should be remembered that,
as shown in clinical trials, patients failing PI/r monothe-
rapy can be successfully treated with the re-introduction
of nucleosides. In this regard, it is important that patients
receiving PI/r monotherapy are regularly monitored to
allow early detection of ‘reversible failures’.
Selection of patients for boosted PI monotherapy
Perhaps the most pertinent question in considering the
initiation of PI/r monotherapy is: who are the best candi-
dates and how can we best identify them? The selection of
patients and the subsequent demonstration of successful
long-term PI/r monotherapy is likely to be critical in the
consolidation of monotherapy as an accepted treatment ap-
proach. The authors of the MONOI study concluded that
good candidates for PI/r monotherapy should have an un-
detectable viral load (HIV-1 RNA at least < 50 copies/mL)
at the time of commencing monotherapy, should be more
adherent than for triple therapy and should have been trea-
ted with antiretroviral therapy (ART) for a sufficient
amount of time before switching to monotherapy [15].
While it is clear that it is important for PI/r monotherapy
candidates to have a substantial period with an undetec-
table viral load, opinions differ with regard to the minimum
duration of viral suppression. Most switching studies have
used a 6-month period with undetectable viral load,
primarily in order to demonstrate that existing therapy was
effective prior to the switch and that the patient was adhe-
rent. Adherence to treatment is important, and patients
who have been stable on HAART for some years and who
have shown no signs of poor compliance would appear to
be suitable, provided that there are no other factors that
would preclude PI/r monotherapy, such as a history of PI
failure. With regard to adherence, in MONOI, 48.5% of
rebounding PI/r monotherapy patients admitted to having
missed at least one treatment dose during follow-up versus
31.6% of other patients [15]. The median duration of prior
ART treatment in rebounding PI/r monotherapy patients
was 5.1 years versus 8.9 years in other patients.
With regards to pre-HAART HIV DNA, in MONOI the
median HIV DNA was 4.2 log10 copies/10
6 cells in patients
with virological rebound during 96 weeks of darunavir/r
monotherapy (24/112 patients, 21.4%) versus 3.9 log10
copies/106 cells in other patients [15]. Furthermore, it was
demonstrated (using ultrasensitive plasma RNA assay and
quantification of total HIV DNA viraemia) that patients in
the MONOI study with the lowest plasma RNA and total
HIV DNA viraemia were the most suitable candidates for
PI/r monotherapy [13,15].
CD4 cell count status is also an important factor when
considering PI/r monotherapy initiation. Analyses to
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cant association between a low baseline CD4 cell count
nadir (< 100–200 cells/μL) and subsequent treatment
failure [11,16]. Furthermore, in patients co-infected with
hepatitis C virus, significantly lower virological response
was observed versus non-co-infected patients [17],
suggesting that hepatitis C co-infection, likely associated
with intravenous drug use, might possibly be a marker
of poor adherence.
Maintaining virological efficacy with boosted PI
monotherapy
A key consideration for the adoption of boosted PI mono-
therapy is to achieve a consensus on what constitutes treat-
ment success. It is also important to demonstrate that
effective viral suppression can be maintained over the long
term. It is worth noting that even with combination
therapy, the current ‘gold standard’ for achieving durable
viral suppression, isolated ‘blips’ (i.e. viral loads that are
transiently detectable, but usually no more than 400 HIV-1
RNA copies/mL), are not uncommon in successfully
treated patients, so some degree of fluctuation in viral load
might also be expected with PI/r monotherapy. In addition
to effective viral suppression, the success of treatment must
also be defined in terms of its tolerability for the patient
and the balance of efficacy/tolerability achieved in relation
to other possible treatment approaches. While the success
of triple-drug HAART in achieving viral suppression is
clear, it is also clear that the long-term success of HAART
has, in part, been limited by drug toxicities and drug inter-
actions, as patients are exposed to multiple drugs for
prolonged periods of time [18,19].
Although plasma HIV RNA < 50 copies/mL is today
consistently considered as undetectable, treatment success
has been defined differently across clinical trials e.g. dif-
ferent primary and secondary endpoints providing different
power calculations and levels of confidence, as well as
different analysis definitions (intent-to-treat [ITT]-time-to-
loss of virological response [TLOVR] and TLOVR non-
virological failure [VF] censored etc.). It is to be hoped that
future studies will adopt similar criteria to assess efficacy
and safety parameters for treatments to make it easier to
compare their findings. Ideally, treatment decisions would
be informed by access to long-term data from controlled
clinical trials and cohort studies, but such data are un-
available for most individual treatments and regimens.
Defining treatment failure also remains challenging, with
different guidelines offering different perspectives based on
different evidence. The EACS guidelines define VF as a
confirmed plasma HIV-1 RNA > 50 copies/mL six months
after starting therapy (initiation or modification) in patients
remaining on ART [2]. In contrast, the US DHHS guide-
lines define VF as a confirmed viral load > 200 HIV-1 RNA
copies/mL, on the basis that it eliminates most cases ofapparent viraemia caused by blips or assay variability [3].
However, given the range of viral load assays available, with
different sensitivities, it remains possible that different
results may be obtained with different assays, such that a
patient might be judged to be ‘borderline’ but still success-
fully treated using one assay, but a ‘failure’ requiring consi-
deration of a change in treatment using another assay.
While boosted PI monotherapy offers the potential for
reduced toxicity, its adoption depends upon the demonstra-
tion of robust efficacy data. Available data show only a
small difference in efficacy between triple-drug HAART
and boosted PI monotherapy following treatment switch
(Figure 2a [lopinavir/r] and 2b [darunavir/r]) and in the
MONET study with darunavir/r monotherapy, effective
viral suppression was maintained up to three years of treat-
ment [20]. Of note, in the five patients with VF on daruna-
vir/r monotherapy in the MONOI study, re-suppression of
viral load (< 50 HIV-1 RNA copies/mL) was successfully
achieved with the addition of two NRTIs to the treatment
regimen. The emergence of PI resistance on PI/r mono-
therapy has been rare and re-introduction of HAART
remains possible in such cases. It is also important to note
that in the PI monotherapy trails reviewed, changes in CD4
cell counts between treatment arms were not considered
significant [7,20,21]. In their systematic review of boosted
PI monotherapy, Bierman et al. reported that mean CD4
cell counts ranged from −40 to +289 cells/μl in patients on
monotherapy against +8 to +240 cells/μl in patients on
HAART [21]. In summary, the available evidence indicates
that, in a large proportion of patients, effective long-term
virological control is possible with boosted PI monotherapy
and if re-suppression is needed this can be achieved with
the re-introduction of NRTIs.
The significance of detectable virus in sanctuary sites
While modern ART can provide effective plasma HIV-1
virus suppression, the importance of viral reservoirs in the
genitals and central nervous system (CNS) remains the
subject of debate. The principal issues surrounding these
reservoirs are whether or not three drugs are still required
to control HIV-1 replication in sanctuary sites when plasma
HIV-1 RNA is fully suppressed, whether all boosted PIs
sufficiently penetrate into the CNS to achieve effective
long-term control, and whether boosted PI monotherapy
controls HIV-1 RNA in the genital tract. Antiretroviral drug
penetration may be important for preventing HIV-1 repli-
cation in the CNS, and observational studies have demon-
strated a correlation between CNS penetration effectiveness
rank (CPE) and HIV-1 levels in the cerebrospinal fluid
(CSF) [22]. Further, darunavir/r and lopinavir/r mono-
therapy have lower CPE scores compared with triple
therapy regimens [23]; although it should be noted that
CPE score has yet not been validated.
Figure 2 Efficacy of a) Lopinavir/r [21] and b) Darunavir/r monotherapy vs comparator arms [7,20]. Efficacy was assessed in the ITT
population and modification of treatment was considered failure in the MONET and MONOI darunavir/r monotherapy trials [7,20]. In the
lopinavir/r monotherapy trials [21], there was some variance in what was considered failure. In OK04 2005, treatment modification = failure. In
OK04 2008, treatment modification≠ failure. In KALMO failure was defined as confirmed HIV-1 RNA > 1,000 copies/mL. In MO6-613 non-
responders were defined as those who either did not complete 96 weeks of treatment, had HIV-1 RNA at > 50 copies/mL at week 96, or
experienced confirmed virological rebound before week 96.
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results in neurotoxicity [23], with a number of clinical
factors associated with its development, including
depression, female gender, low CD4 count, advancing
age and drug abuse [24,25]. Consequently, an important
question is to what degree plasma viral suppression to <
50 HIV-1 RNA copies/mL translates into effective viral
suppression in the CNS. It has been suggested that CSF
viral load data could be obtained as part of the decision
to initiate therapy. In this regard, in the CHARTER
study, 96% of patients with undetectable plasma HIV-1
RNA on a triple regimen also had a suppressed CNS
viral load [23], indicating that most patients on HAART
have effective suppression of HIV-1 in the CNS.
Conversely, since NRTIs potentially have adverse
effects on the CNS, monotherapy with boosted PIs
have the possible advantage to the CNS of removal
of NRTI toxicity. The NRTIs are known to penetrate
the CNS and have been associated with improve-
ments in cerebral function. However, administration
of the NRTIs can also result in mitochondrial toxici-
ties through CNS penetration. Indeed, several NRTIshave been shown to possess the potential to damage
brain tissue and neurones [26,27]. Hence, the use of
PI/r monotherapy could decrease some of the CNS
toxicities associated with combination therapy.
The current EACS guidelines define potentially
CNS-active drugs as antiretrovirals with either demon-
strated clear CSF penetration when studied in HIV-
infected populations (CSF concentration above the
90% inhibitory concentration [IC90] in > 90% of exam-
ined patients), or with proven short-term (3–6 months)
efficacy with respect to cognitive function or CSF viral
load decay when evaluated as single agents or in con-
trolled studies in peer reviewed papers. According to
this definition, agents with demonstrated clear CSF
penetration are the NRTIs zidovudine and abacavir,
the NNRTIs efavirenz and nevirapine, the boosted PIs
darunavir/r, lopinavir/r and indinavir/r, and the entry
inhibitor maraviroc, while agents with ‘proven efficacy’
are the NRTIs zidovudine, stavudine and abacavir, and
the boosted PI lopinavir/r [2].
With regard to the genital reservoir for HIV, in a
MONOI sub-study investigating the penetration of
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concentration was 6-fold higher than the darunavir 50%
effective concentration (EC50) against wild-type HIV-1,
with the median concentration close to the blood plasma
free fraction [28]. In females, in the IMANI-2 study of
lopinavir/r first-line monotherapy, lopinavir/r penetra-
tion into the cervicovaginal fluid exceeded the reference
population median IC50 value in all but one sample
tested [29].
The available data indicate that both darunavir and
lopinavir show moderately good CNS penetration,
with both showing high penetration into the genital
tract. However, further studies are needed to confirm
these findings.
Safety and tolerability benefits with boosted PI
monotherapy
One of the main attractions of a switch from multi-drug
HAART to boosted PI monotherapy is the potential safety
benefit that may result from its use. The tolerability issues
of NRTIs in particular are well known, these agents being
associated with increased risk of insulin resistance,Figure 3 a) Abbott 613 trial: Changes in limb fat over time [30] b) MONOsecondary dyslipidaemia and lipodystrophy/atrophy.
Reduced BMD and renal disease may also result with
some HAART regimens. Lipodystrophy seems to be asso-
ciated with particular NRTIs, with regimens containing
stavudine or zidovudine appearing to confer highest risk
[30]. Data from the M03-613 study in treatment-naïve
patients taking lopinavir/r (Figure 3a) and the MONOI
trial with darunavir/r (Figure 3b) indicate that boosted PI
monotherapy is not associated with the limb fat loss that
is observed with some NRTIs [31,32], although longer-
term tolerability data are required to confirm the findings.
When considering BMD, while there was a slightly
greater decrease in BMD in lopinavir/r monotherapy-
treated patients versus triple-therapy patients over 96 weeks
in the M03-613 study, in the 48-week MONARCH study
in 30 virologically suppressed patients, the switch to daru-
navir/r monotherapy was associated with a trend for
improvement in BMD (and in body fat distribution with
stable limb fat and a decrease in visceral adipose tissue)
[33]. While long-term data are required, available data indi-
cate that switching to boosted PI monotherapy does not
adversely affect BMD. It should be noted, however, thatI: Median change in limb fat from baseline to week 48 [31].
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protein cholesterol with PI/r monotherapy versus triple
therapy in MONARCH, though this may reflect the fact
that some patients in the triple therapy arm were taking
tenofovir, which has a direct lipid-lowering effect [34].
Renal toxicity is a well-recognised risk with tenofovir
disoproxil fumarate therapy [35]. From this perspective,
boosted PI monotherapy would appear to be a useful treat-
ment option for patients with tenofovir-related renal
disease. Finally, while concerns have been expressed about
potential CSF viral escape with PI/r monotherapy, after
144 weeks of darunavir/r monotherapy in the MONET
study there was no significant difference in the observed
change in cognitive functioning between the mono- and
triple therapy treatment groups (although the study was
not powered to detect differences in neurologic impair-
ment) [36].
Future development of boosted PI monotherapy:
ongoing and planned studies
While available data indicate that the switch from multi-
drug HAART to boosted PI monotherapy in suitable
patients represents an attractive treatment option, there
remain some questions to be answered, in particular rela-
ting to long-term efficacy and tolerability, and efficacy in
CNS and genital ‘reservoirs’ (although in the latter case this
is also true for triple therapy).
Two ongoing studies of boosted PI monotherapy are
expected to provide a wealth of new efficacy and tolerabi-
lity data: PIVOT (PI monotherapy Vs Ongoing Triple-
therapy in the long-term management of HIV infection)
and PROTEA, (PROTEAse inhibitor [darunavir/r] in
mono- or triple therapy in suppressed HIV-1-infected
patients). The PIVOT trial planned to include 560 patients
in the UK and be of 5 years’ duration. Patients with a
plasma viral load < 50 HIV-1 RNA copies/mL at screening
(and for at least 24 weeks prior to screening) and a CD4
cell count > 100 cells/mm3 are included in the study,
which compares boosted PI monotherapy to combination
HAART with two NRTIs and either an NNRTI or a PI
(boosted or un-boosted). This study, which includes geni-
tal secretions and CNS sub-studies, will also measure
effects on quality of life, neurocognitive function, cardio-
vascular risk and costs.
The phase IIIb PROTEA study is investigating the effi-
cacy and tolerability of darunavir/r monotherapy versus
darunavir/r-containing triple therapy in approximately 260
virologically suppressed (for at least 48 weeks) HIV-1-
infected patients. The primary objective is to demonstrate
the non-inferior efficacy of darunavir/r monotherapy (with
respect to the percentage of patients with viral load < 50
HIV-1 RNA copies/mL at 48 weeks post-switch to mono-
therapy) versus triple therapy containing darunavir/r. This
study will also assess changes in neurocognitive functionover 48 and 96 weeks of treatment and whether there is
any correlation between plasma and CSF viral load and
neurocognitive function. In addition, PROTEA will study
the evolution of the viral genotype and determine whether
there is any loss of treatment options at weeks 48 and 96,
as defined by the emergence of phenotypic drug resistance.
Summary and conclusions
The switch from triple-drug combination therapy to
boosted PI monotherapy appears to be a promising stra-
tegy to maintain antiviral efficacy. Available data from PI/r
monotherapy trials are encouraging, showing slightly
lower efficacy than triple therapy regimens. However,
further data – particularly with regard to the long-term
efficacy and tolerability of treatment – are required before
this approach can be recommended as a routine treatment
option. In this regard, further studies are ongoing, which
will further elucidate the long-term utility of boosted PI
monotherapy. In the meantime, the available data indicate
that the most suitable candidates for the use of boosted PI
monotherapy are long-term virologically suppressed
patients who have demonstrated good adherence to ART,
have no history of PI failure, do not have chronic hepatitis
B, do not have HIV-associated neurocognitive disorders
and who are able to tolerate low dose ritonavir.
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